Quick facts about DMPA-SC
(Sayana® Press)

- 99 percent effective at preventing unintended pregnancy when given correctly and on time every three months. Does not protect from HIV and other sexually transmitted infections.
- Lower dose of contraceptive hormone than intramuscular DMPA.
- Small and light, with a short needle.
- Easy to use, including by community health workers and women themselves (self-injection).
- Stable at room temperature (15°C–30°C).
- Three-year shelf life.
- Available in at least 20 FP2020 countries.*
- Can be purchased at US$0.85 per dose by qualified buyers (including ministries of health in FP2020 countries).

Costs and cost-effectiveness of subcutaneous DMPA through different delivery channels:
What new evidence tells us

Family planning is one of the smartest investments a government can make. Ensuring access to contraception not only advances women’s health and rights but also saves lives and money. When offered as part of a broad method mix, a new type of injectable called subcutaneous DMPA (DMPA-SC or Sayana® Press*) is making it easier for women to access contraception through a variety of delivery channels, including self-injection.

Recent evidence from African countries indicates that DMPA-SC may help reduce service delivery costs by catalyzing community-based distribution and remote provision of injectable contraception. Moreover, self-injection of DMPA-SC—when compared with clinic administration of traditional injectables—is not just cost-effective but cost saving when accounting for costs to both women and health systems.

Advancing contraceptive choice, access, and use with DMPA-SC

DMPA-SC is an innovative product that is expanding women’s access to contraception when provided as part of a country’s family planning (FP) program. The DMPA-SC product available today (Sayana Press) combines the contraceptive drug and needle into a single unit that is small and easy to use. When compared with traditional intramuscular DMPA (DMPA-IM), DMPA-SC has a lower dose and shorter needle and is easier to administer. DMPA-SC is suitable for inclusion in all service delivery channels in both the public and private sectors and even enables women to self-inject with training.

*FP2020 aims to expand access to family planning information, services, and supplies to an additional 120 million women and girls in 69 of the world’s poorest countries.

*DMPA stands for depot medroxyprogesterone acetate. Sayana Press is a registered trademark of Pfizer Inc.
New evidence shows that women who self-inject DMPA-SC continue using injectable contraception longer than those who receive injections from providers, which translates to fewer unintended pregnancies.\textsuperscript{1,2,3,4}

DMPA-SC is currently being piloted, introduced, or scaled up in more than 20 FP2020 countries. As of May 2017, it can be purchased at US$0.85 per dose for qualified buyers—\textsuperscript{a} a price similar to DMPA-IM. Several recent studies have examined the costs and cost-effectiveness of DMPA-SC when delivered through different channels, including self-injection.

Understanding costs and cost-effectiveness of DMPA-SC through new research

Key finding: DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels that are closer to women.

What the study looked at: PATH conducted costing studies in Burkina Faso, Senegal, and Uganda to estimate the costs of delivering DMPA-SC and DMPA-IM across different delivery approaches and channels. Costs included both direct medical/health systems costs—such as commodity costs and provider time—and nonmedical costs, such as costs women incur when traveling to, waiting for, and receiving services. It assumed the US$0.85 commodity cost for DMPA-SC. The studies were not designed to compare estimated costs across countries.

What the study found:

- **Total delivery costs were lowest for channels that are closer to women.** Specifically, they were lowest for community-based distribution followed closely by self-injection. Costs were highest for facility-based administration.

- **Costs for women only, in terms of their time and travel, were lowest for self-injection.**

- **There was no major difference in total costs between DMPA-SC and DMPA-IM when administered by the same type of health worker in the same setting.**

| Total direct costs of DMPA-SC over four injections (in 2016 US dollars) |
|---------------------------------|------------------|
| UGANDA                          |                  |
| DMPA-SC (community-based distribution) | $7.69            |
| DMPA-IM (community-based distribution) | $7.71            |
| Self-injection (DMPA-SC)        | $7.83            |
| DMPA-IM (facility-based delivery) | $10.12           |
| SENEGAL                         |                  |
| Self-injection (DMPA-SC)        | $8.38            |
| DMPA-IM (facility-based delivery) | $9.46            |
| BURKINA FASO                    |                  |
| DMPA-SC (facility-based delivery) | $12.14           |
| DMPA-IM (facility-based delivery) | $11.60           |

\textsuperscript{a}This pricing reflects a six-year agreement. During the six years (2017–2022), the price is guaranteed at US$0.85. After the agreement, Pfizer Inc. is committed to ensuring the product continues to be available at an affordable price.

\textsuperscript{**}Data presented reflect a lower-cost training approach to self-injection that was being used at the time of data analysis, namely, the replacement of a client instruction booklet with a less expensive one-page client instruction sheet.
What this means for policy and programming:

▶ Bringing injectable contraceptive service delivery closer to women may cost less than facility delivery of injectables and reduce barriers to access.
▶ The option to self-inject with DMPA-SC may further reduce financial and logistical barriers for women.
▶ When making decisions about injectable contraceptive programming, the benefits of DMPA-SC—such as ease of use, women and provider preferences for the product over DMPA-IM, and improved rates of contraceptive continuation with self-injection—can be emphasized given that delivery costs between DMPA-SC and DMPA-IM are similar for the same type of health worker in the same setting.

Key finding: Self-injection of DMPA-SC is cost saving when costs to women and health systems are considered

What the study looked at:

PATH performed an evaluation to explore whether self-injected DMPA-SC is cost-effective when compared with DMPA-IM administered by health workers in Uganda. Based on the experiences of real women participating in self-injection research studies, modeling was applied to a hypothetical group of 1 million injectable contraception users to estimate the incremental costs per pregnancy averted and per disability-adjusted life year (DALY) averted over a one-year period. Like the previous study, it assumed the US$0.85 commodity cost for DMPA-SC.

What the study found:

▶ Self-injected DMPA-SC yields greater health impact. Self-injected DMPA-SC could prevent 11,101 additional unintended pregnancies and avert 1,683 DALYs compared with facility-administered DMPA-IM.

▶ Self-injected DMPA-SC is cost saving when considering costs to both women and health systems. Self-injected DMPA-SC was shown to save up to $1.1 million per year when accounting for total costs to society, which include costs to both women and health systems.
Self-injected DMPA-SC can be cost-effective when considering costs to health systems only. As noted above, the health impact of self-injected DMPA-SC is greater due to the increased continuation rates. While costs to health systems alone were found to be higher for self-injected DMPA-SC than for DMPA-IM—largely due to the costs of self-injection training during the first visit—simplifying the client training approach can reduce the costs of self-injected DMPA-SC to the point where it is cost-effective from a health systems perspective. For example, self-injection is cost-effective when using a lower-cost one-page visual aid for clients in place of a booklet and limiting the number of practice injections.

What this means for policy and programming:

When including health system and women’s time and travel costs, self-injected DMPA-SC costs less and leads to better health outcomes than facility-administered DMPA-IM, suggesting that self-injected DMPA-SC is a commonsense approach.

It is important to design a client training approach that is feasible, affordable, and effective. To assist program implementers with this endeavor, PATH is conducting the Self-Injection Best Practices Project in Uganda (2016–2018) that will help determine the optimal approach to client training and program delivery in terms of both costs and outcomes.

Applying new evidence to DMPA-SC introduction and scale-up

A variety of factors must be evaluated when determining whether to introduce and scale up a next-generation contraceptive like DMPA-SC. New data on the costs and cost-effectiveness of DMPA-SC through different delivery channels provide decision-makers with compelling reasons to consider updating policies and programs to include DMPA-SC at all levels of care, including self-injection.

References